Glutamate antagonists for Parkinson's disease: Rationale for use and therapeutic implications

CNS Drugs

Volumn 9, Issue 6, 1998, Pages 421-429

  Cooper, Alison J ^a   Carroll, Camille B ^a   Mitchell, Ian J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ATAXIA; COGNITIVE DEFECT; DYSKINESIA; HUMAN; NEUROPROTECTION; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEDATION;

EID: 0031799220     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809060-00001     Document Type: Review

References (43)

1. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1: 345-9
2. Wichmann T, Delong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996; 6: 751-8
3. Mitchell IJ, Clarke CE, Boyce S, et al. Neural mechanisms underlying Parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989; 32: 213-26
4. Collingridge GL, Lester RAJ. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 1989; 41 (2): 143-210
5. Schoepfer R, Monyer H, Sommer B, et al. Molecular biology of glutamate receptors. Prog Neurobiol 1994; 42 (2): 353-7
6. Carlsson M, Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989; 75: 221-6
7. Carroll CB, Holloway V, Brotchie JM, et al. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology 1995; 119: 55-65
8. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monamine-depleted rats. Ann Neurol 1990; 28: 539-46
9. Carlsson M, Svensson A. Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol Biochem Behav 1990; 36: 45-50
10. Carlsson M, Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 1989; 77: 65-71
11. Starr MS, Starr BS. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice. Psychopharmacology 1994; 114: 469-76
12. Martin P, Svensson A, Carlsson A, et al. On the roles of dopamine D1 vs D2 receptors for the hyperactivity response elicited by MK-801. J Neural Transm Gen Sect 1994; 95: 113-21
13. Domino EF, Sheng J. NMDA antagonist and dopamine D-1 and D-2 agonist interactions in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 1993; 264: 221-5
14. Crossman AR, Peggs D, Boyce S, et al. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 1989; 28 (11): 1271-3
15. Rupniak NM, Boyce S, Tye S, et al. Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primates. Pharmacol Biochem Behav 1993; 44 (1): 153-6
16. Wullner U, Kupsh A, Arnold G. The competitive NMDA antagonist CGP 40116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology 1992; 31: 713-5
17. Mitchell IJ, Hughes N, Carroll CB, et al. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of EAA and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav Pharmacol 1995; 6: 492-508
18. Mitchell IJ, Carroll CB. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci Biobehav Rev 1997; 21 (4): 469-75
19. Stauch Slusber B, Rissolo KC, Anzilotti KF, et al. Centrally-administered AMPA antagonist increase locomotion in parkinsonian rats. J Neural Transm Park Dis Dement Sect 1995; 9: 145-9
20. Klockgether T, Turski I. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991; 30: 717-23
21. Luquin MR, Obeso JA, Laguna J, et al. The AMPA receptor antagonist NBQX does not after the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 1993; 235: 297-300
22. Maneuf Y, Mitchell IJ, Crossman AR, et al. Functional implications of kappa opiate receptor mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995; 683: 102-8
23. Svensson A, Carlsson ML. Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotur stimulation. Neuropharmacology 1992; 31 (5): 513-8
24. Brotchie JM, Mitchell IJ, Sambrook MA, et al. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 1991; 6 (2): 133-8
25. Mitchell IJ, Brotchie JM, Cooper AJ, et al. Reversal of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in the primate. Eur J Neurosci 1991; 4 Suppl.: 4050
26. Rison RA, Stanton PK. Long-term potentiation and N-methyl-D-aspartate receptors - foundations of memory and neurologic disease. Neurosci BioBehav Rev 1995; 19: 533-52
27. Parada J, Czuczwar SJ, Turski WA. NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil. Cog Brain Res 1992; 1: 67-71
28. Porter RHP, Greenamyre JT. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 1995; 64: 614-23
29. Standaert DG, Testa CM, Young AB, et al. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994; 343: 1-16
30. Williams K, Russell SL, Shen YM, et al. Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 1993; 10: 267-78
31. Choi DWJ. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-76
32. Small DL, Buchan AM. NMDA antagonists: their role in neuroprotection. Int Rev Neurobiol 1997; 40: 137-71
33. Turski L, Bressler K, Rettig KJ, et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349: 414-8
34. Paquet M, Tremblay M, Soghomonian JJ, et al. AMPA and NMDA glutamate receptor subunits in midbrain dopaminergic neurons in the squirrel monkey: an immunohistochemical and in situ hybridization study. J Neurosci 1997; 4: 1377-96
35. Cooper JM, Schapira AHV. Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr 1997; 29: 175-83
36. Fix AS, Long GG, Wozniak DF, et al. Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: a review. Drug Dev Res 1994; 32: 147-52
37. Mitchell IJ, Cooper AJ, Griffiths, MR, et al. Phencyclidine and corticosteroids induce apoptosis of a subpopulation of striatal neurons: a neural substrate for psychosis? Neuroscience 1998; 84: 489-501
38. Klockgether T, Jacobsen P, Loschmann PA, et al. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm Park Dis Dement Sect 1993; 5: 101-6
39. 39l. Danysz W, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents. Neurosci Biobehav Rev 1997; 21: 455-68
40. Montastruc JL, Rascol O, Senard JM, et al. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 85 (7): 630-1
41. Dragunow M, Faull RLM. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 1986; 24: 261-5
42. Robertson HA, Peterson MR, Murphy K, et al. D1 dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour. Brain Res 1989; 503: 346-9
43. Cooper AJ, Mitchell IJ, Fos immuno-positive neurons in the subthalamic nucleus following reversal of parkinsonian symptoms by antagonism of excitatory amino acid transmission in the entopeduncular nucleus of the monoamine-depleted rat. Neurosci Lett 1995; 201: 251-4